Compare DexCom, Inc. (DXCM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Merck & Co., Inc. — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while Merck & Co., Inc. trades at $146.07 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 11× DexCom, Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Merck & Co., Inc. for 98 Days on average.
| DXCM | MRK | |
|---|---|---|
Market Cap | $31.86B | $351.28B |
Volume | 3,607,070 | 7,969,665 |
Sector | Health | Health |
52-Week High | $92.34 | $156.43 |
52-Week Low | $54.84 | $82.49 |
Typical Hold Time | 62 Days | 98 Days |
Enterprise Value | $31.32B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
